Rami Doueiri
Research Subjects
Rami Doueiri has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Akiko Futamura
Hinge Therapeutics, Los Angeles, CA
1 shared publicationAntonio Valentin
Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA
1 shared publication- Barbara K. Felber
Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA
1 shared publication - Bhabadeb Chowdhury
Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA
1 shared publication - Brandon F. Keele
AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research
1 shared publication - Candido Alicea
Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA
1 shared publication
Latest Publications
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 1752
Abstract 1752: Switchable binding of TecApta to Atezolizumab provides the possibility of enhancing the therapeutic effects of this immune checkpoint inhibitor
One of the main goals of cancer therapeutics is to develop smart molecules that can deliver drugs or immunogens to cancer cells within the tumor, while avoiding the toxicity to normal cells. Lately, immune checkpoint inhibitors have shown significant effects in the field of cancer treatment. Atezolizumab is an immune check point inhibitor specific to PD-L1. In order to potentiate anti-tumor aspects of Atezolizumab, we have developed TecApta, a switchable single strand DNA oligonucleotide aptamer that specifically binds to this antibody with a high affinity and specificity. However, TecApta is detached from Atezolizumab upon binding of this antibody to its target PD-L1. This switchable aspect of TecApta makes it a suitable drug carrier for targeting cancer cells within the tumor microenvironment. We have developed modified versions of TecApta which include either the chemotherapy drug, gemcitabine, or the immune activator, TLR9A. Based on our in vitro data, both versions are biologically active. The gemcitabine sensitive cell line MDA-MB-231/Luc exhibits similar IC50s (20nM) for both gemcitabine-linked-TecApta (GMZ-TecApta) and the free unbound gemcitabine. Moreover, the same concentrations of TLR9A-linked-TecApta (TLR9A-TecApta) and the free TLR9A show similar effects in inducing TLR9 receptors in a cell-based assay. These results suggest that possibly GMZ-TecApta and TLR9A-TecApta can be carried by Atezolizumab and released within the tumor microenvironment, where they may induce apoptosis or aggravate an immune reaction, respectively. Animal studies will be conducted in the future to investigate the possibility of such favorable outcomes. Citation Format: Mohammad Sadegh Atefi, Sola Takahashi, David Sich, Jessica Grondin, Rami Doueiri, Lindsay Bourgeois, Gary Olsem, Akiko Futamura, Julie Yang, Joan Oliva, John Elshimali, Carlos Pereira. Switchable binding of TecApta to Atezolizumab provides the possibility of enhancing the therapeutic effects of this immune checkpoint inhibitor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1752.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 1752
Open AccessAbstract 1752: Switchable binding of TecApta to Atezolizumab provides the possibility of enhancing the therapeutic effects of this immune checkpoint inhibitor
One of the main goals of cancer therapeutics is to develop smart molecules that can deliver drugs or immunogens to cancer cells within the tumor, while avoiding the toxicity to normal cells. Lately, immune checkpoint inhibitors have shown significant effects in the field of cancer treatment. Atezolizumab is an immune check point inhibitor specific to PD-L1. In order to potentiate anti-tumor aspects of Atezolizumab, we have developed TecApta, a switchable single strand DNA oligonucleotide aptamer that specifically binds to this antibody with a high affinity and specificity. However, TecApta is detached from Atezolizumab upon binding of this antibody to its target PD-L1. This switchable aspect of TecApta makes it a suitable drug carrier for targeting cancer cells within the tumor microenvironment. We have developed modified versions of TecApta which include either the chemotherapy drug, gemcitabine, or the immune activator, TLR9A. Based on our in vitro data, both versions are biologically active. The gemcitabine sensitive cell line MDA-MB-231/Luc exhibits similar IC50s (20nM) for both gemcitabine-linked-TecApta (GMZ-TecApta) and the free unbound gemcitabine. Moreover, the same concentrations of TLR9A-linked-TecApta (TLR9A-TecApta) and the free TLR9A show similar effects in inducing TLR9 receptors in a cell-based assay. These results suggest that possibly GMZ-TecApta and TLR9A-TecApta can be carried by Atezolizumab and released within the tumor microenvironment, where they may induce apoptosis or aggravate an immune reaction, respectively. Animal studies will be conducted in the future to investigate the possibility of such favorable outcomes. Citation Format: Mohammad Sadegh Atefi, Sola Takahashi, David Sich, Jessica Grondin, Rami Doueiri, Lindsay Bourgeois, Gary Olsem, Akiko Futamura, Julie Yang, Joan Oliva, John Elshimali, Carlos Pereira. Switchable binding of TecApta to Atezolizumab provides the possibility of enhancing the therapeutic effects of this immune checkpoint inhibitor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1752.
- Open Access
- 1 August 2018
- Published by American Society for Microbiology in Journal of Virology
- Vol. 92 (15) , e00281-18
Control of Heterologous Simian Immunodeficiency Virus SIV smE660 Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques
An effective AIDS vaccine continues to be of paramount importance for the control of the pandemic, and it has been proven to be an elusive target. Vaccine efficacy trials and macaque challenge studies indicate that protection may be the result of combinations of many parameters. We show that a combination of DNA and protein vaccinations applied at the same time provides rapid and robust cellular and humoral immune responses and evidence for a reduced risk of infection. Vaccine-induced neutralizing antibodies and Env V2-specific antibodies at mucosal sites contribute to the delay of SIV smE660 acquisition, and genetic makeup (TRIM-5α) affects the effectiveness of the vaccine. These data are important for the design of better vaccines and may also affect other vaccine platforms.
- 1 August 2018
- Published by American Society for Microbiology in Journal of Virology
- Vol. 92 (15) , e00281-18
Open AccessControl of Heterologous Simian Immunodeficiency Virus SIV smE660 Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques
An effective AIDS vaccine continues to be of paramount importance for the control of the pandemic, and it has been proven to be an elusive target. Vaccine efficacy trials and macaque challenge studies indicate that protection may be the result of combinations of many parameters. We show that a combination of DNA and protein vaccinations applied at the same time provides rapid and robust cellular and humoral immune responses and evidence for a reduced risk of infection. Vaccine-induced neutralizing antibodies and Env V2-specific antibodies at mucosal sites contribute to the delay of SIV smE660 acquisition, and genetic makeup (TRIM-5α) affects the effectiveness of the vaccine. These data are important for the design of better vaccines and may also affect other vaccine platforms.